Cytokines and bone loss in a 5-year longitudinal study hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: The Danish Osteoporosis Prevention Study

Journal of Bone and Mineral Research

Volumn 15, Issue 8, 2000, Pages 1545-1554

  Abrahamsen, Bo ^a   Bonnevie Nielsen, Vagn ^b   Ebbesen, Ebbe Nils ^a   Gram, Jeppe ^a   Beck Nielsen, Henning ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Bone mineral density; Cytokines; Hormone replacement therapy; Interleukin 6; Menopause

Indexed keywords

CYTOKINE; ESTRADIOL; FOLLITROPIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6 RECEPTOR; NORETHISTERONE ACETATE;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE SUBSTITUTION; HUMAN; LONGITUDINAL STUDY; MULTICENTER STUDY; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

EID: 0033915371     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2000.15.8.1545     Document Type: Article

References (56)

1. Pouilles JM Tremollieres F, Ribot C 1993 The effects of menopause on longitudinal bone loss from the spine. Calcif Tissue Int 52:340-343.
2. Lindsay R, Tohme JF 1990 Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 76: 290-295.
3. Moore M, Bracker, M Sartoris D, Saltman P, Strause L 1990 Long-term estrogen replacement therapy in postmenopausal women sustains vertebral bone mineral density. J Bone Miner Res 5:659-664.
4. Nielsen SP, Bärenholdt O, Hermansen F, Munk-Jensen N 1994 Magnitude and pattern of skeletal response to long term continous and cyclic sequential oestrogen/progestin treatment. Br Obstet Gynaecol 101:319-324.
5. Pacifici R 1996 Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11:1043-1051.
6. Manolagas SC, Jilka RL 1995 Bone marrow, cytokines and bone remodeling. N Engl J Med 332:305-311.
7. Fuller K, Wong B, Fox S. Choi Y, Chambers TJ 1998 TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188: 997-1001.
8. Jilka RL 1998 Cytokines, bone remodelling, and estrogen deficiency: A 1998 update. Bone 23:75-81.
9. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, Morinaga T, Toyama Y, Yabe Y, Higashio K, Suda T 1998 Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 246:199-204.
10. Eisenberg SP, Evans RJ, Arend WP, Verdeerber E, Brewer, MT, Hannum CH, Thompson RC 1990 Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343:341-346.
11. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, et al. 1993 Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 90:11924-11928.
12. Fagiolo U, Cossarizza A, Scala E, Fanales Belasio E, Ortolani C, Cozzi E, Monti D, Franceschi C, Paganelli R 1993 Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 23:2375-2378.
13. Kania DM, Binkley N, Checovich M, Havighurst T, Schilling M, Ershler WB 1995 Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density. J Am Geriatr Soc 43:236-239.
14. Girasole G, Jilka R, Passeri G, Boswell S, Boder G, Williams D, Manolagas S 1992 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estro-gens. J Clin Invest 89:883-891.
15. Kassem M, Harris SA, Spelsberg TC, Riggs BL 1996 Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors. J Bone Miner Res 11:193-199.
16. Kassem M Khosla S, Spelsberg TC, Riggs BL 1996 Cytokine production in the bone marrow microenvironment: Failure to demonstrate estrogen regulation in early postmenopausal women. J Clin Endocrinol Metab 81:513-518.
17. Cohen-Solal ME, Graulet AM, Denne MA, Gueris J, Baylink D, De Vernejoul MC 1993 Peripheral monocyte culture supernatants of menopausal women can induce bone resorption: involvement of cytokines. J Clin Endocrinol Metab 77:1648-1653.
18. Rogers A, Eastell R 1998 Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood. J Bone Miner Res 13:1577-1586.
19. Girasole G, Pedrazzoni M, Giuliani N, Passeri G, Passeri M 1995 Increased serum soluble interleukin-6 receptor levels are induced by ovariectomy, prevented by estrogen replacement and reversed by alendronate administration. J Bone Miner Res 10:S161 (abstract).
20. Chen JT, Maruo N, Kato T, Hasumi K, Ogata E, Shiraki M, Morita I 1995 Serum level of soluble interleukin 6 receptor, not interleukin 6, is correlated with bone resorption markers and lumbar bone mineral density after menopause. J Bone Miner Res 10(Suppl 1):M378 (abstract).
21. Maruo N, Chen JT, Ogata E, Shiraki M, Morita I 1996 Serum level of soluble interleukin 6 receptor is correlated with the change of bone metabolism during estrogen therapy. J Bone Miner Res 11(Suppl 1):S118 (abstract).
22. McKane WR, Khosla S, Peterson JM, Egan K, Riggs BL 1994 Circulating levels of cytokines that modulate bone resorption: Effects of age and menopause in women. J Bone Miner Res 9:1313-1318.
23. Pacifici R, Vannice JL, Rifas L, Kimble RB 1993 Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: Effects of menopause and estrogen/ progesterone therapy. J Clin Endocrinol Metab 77:1135-1141.
24. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ 1999 Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 130:545-553.
25. Brett KM, Madans JH 1997 Use of postmenopausal hormone replacement therapy: Estimates from a nationally representative cohort study. Am J Epidemiol 145:536-545.
26. Ralston SH 1994 Analysis of gene expression in human bone biopsies by polymerase chain reaction: Evidence for enhanced cytokine expression in postmenopausal osteoporosis. J Bone Miner Res 9:883-890.
27. Abrahamsen B, Shalhoub V, Larson E, Eriksen EF, Beck-Nielsen H, Marks SC Jr 2000 Cylokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women Bone 26:137-145.
28. Cohen Solal ME, Boitte F, Bernard Poenaru O, Denne MA, Graulet AM, Brazier M, De Vernejoul MC 1998 Increased bone resorbing activity of peripheral monocyte culture supernatants in elderly women. J Clin Endocrinol Metab 83:1687-1690.
29. Zheng SX, Vrindts Y, Lopez M, De Groote D, Zangerle P. F, Collette J, Franchimont N, Geenen V, Albert A, Reginster JY 1997 Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas 26:63-71.
30. Salamone LM, Whiteside T, Friberg D, Epstein RS, Kuller LH, Cauley JA 1998 Cytokine production and bone mineral density at the lumbar spine and femoral neck in premenopausal women. Calcif Tissue Int 63:466-470.
31. Abrahamsen B, Bendtzen K, Beck-Nielsen H 1997 Cytokines and T-lymphocyte subsets in healthy postmenopausal women: Estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. Bone 20:251-258.
32. Eisenberg SP, Brewer MT, Verdeerber E, Heimdal P, Brandhuber BJ, Thompson RC 1991 Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: Evolution of a cytokine control mechanism. Proc Natl Acad Sci USA 88:5232-5236.
33. Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R 1994 Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest 94:2397-2406.
34. Keen RW, Woodford-Richens KL, Lanchbury JS, Spector TD 1998 Allelic variation at the Interleukin-1 receptor antagonist gene is associated with early postmenopausal hone loss at the spine. Bone 23:367-371.
35. Leslie CA, Dubey DP 1994 Increased PGE2 from human monocytes isolated in the luteal phase of the menstrual cycle. Implications for immunity? Prostaglandins 47:41-54.
36. Polan ML, Kuo A, Loukides J, Bottomly K 1990 Cultured human luteal peripheral monocytes secrete increased levels of interleukin-1. J Clin Endocrinol Metab 70:480-484.
37. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC 1992 Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257:88-91.
38. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F 1994 Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13:1189-1196.
39. Kimble RB, Bain S, Pacifici R 1997 The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 12:935-941.
40. Stein B, Yang MX 1995 Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 15:4971-4979.
41. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW 1994 Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83:113-118.
42. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK 1998 IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101:311-320.
43. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V 1994 Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 180:1243-1250.
44. Abrahamsen B, Hansen TB, Jensen LB, Hermann AP, Eiken P 1997 Site of osteodensitometry in perimenopausal women: Correlation and limits of agreement between anatomic regions. J Bone Miner Res 12:1471-1479.
45. Malpe R, Baylink DJ, Linkhart TA, Wergedal JE, Mohan S 1997 Insulin-like growth factor (IGF)-I, -II, IGF binding proteins (IGFBP)-3,-4 and -5 levels in the conditioned media of normal human bone cells are skeletal site-dependent. J Bone Miner Res 12:423-430.
46. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T, Thorner M 1998 Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. J Clin Endocrinol Metab 83:382-393.
47. Cosman F, Lindsay R 1998 Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif Tissue Int 62:475-480.
48. Thorsen K, Kristoffersson AO, Lorentzon RP 1997 Changes in bone mass and serum markers of bone metabolism after parathyroidectomy. Surgery 122:882-887.
49. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud, K E 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541.
50. Munk-Jensen N, Nielsen SP, Obel EB, Eriksen PB 1988 Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: A double blind placebo controlled study. BMJ 296:1150-1152.
51. Stock JL, Coderre JA, McDonald B, Rosenwasser LJ 1989 Effects of estrogen in vivo and in vitro on spontaneous interleukin-1 release by monocytes from postmenopausal women. J Clin Endocrinol Metab 68:364-368.
52. Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, McCracken R, Avioli LE 1991 Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A 88:5134-5138.
53. Hustmyer FG, Walker E, Yu XP, Girasole G, Sakagami Y, Peacock M, Manolagas SC 1993 Cytokine production and surface antigen expression by peripheral blood mononuclear cells in postmenopausal osteoporosis. J Bone Miner Res 8:51-59.
54. Khosla S, Peterson JM, Egan K, Jones JD, Riggs BL 1994 Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab 79:707-711.
55. Hogasen AK, Nordsletten L, Aasen AO, Falch JA 1995 There is no difference in spontaneous and 17 beta-estradiol-induced interleukin-1 beta release by peripheral blood mononuclear cells from nonosteoporotic women with different rates of early postmenopausal bone loss. J Clin Endocrinol Metab 80:2480-2484.
56. Cantatore FP, Loverro G, Ingrosso AM, Lacanna R, Sassanelli E, Selvaggi L, Carrozzo M 1995 Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin Rheumatol 14:157-160.